Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

CAREMARK ADDING $200 MIL. IN HOME INFUSION SALES WITH CRITICAL CARE AMERICA

This article was originally published in The Gray Sheet

  • News

Executive Summary

CAREMARK ADDING $200 MIL. IN HOME INFUSION SALES WITH CRITICAL CARE AMERICA acquisition. The $175 mil. cash acquisition was announced as a definitive agreement with CCA parent Medical Care America Jan. 17. Critical Care America's home infusion sales were "over $200 mil." in 1993, the firm said, enough to rank it among the top five home infusion companies. Caremark does not break out the sales of its home infusion operations.

Table

View full table

Tags:
Latest Headlines

News We’re Watching: Neuralink’s Blindsight Gets FDA Breakthrough Device Tag; FDA Pump Recalls, Guidances; Discure, DeepLook Bolster Coffers

‘You Can Get Paid’: Medtronic CEO On Monetizing AI

Digital Tech Convergence Is Transforming Health Care - LSX Panel

FDA Publishes Final Guidance For Sponsors Of Decentralized Clinical Trials

See All
UsernamePublicRestriction

Register

MT001765

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By